financetom
Business
financetom
/
Business
/
Southwest director buys 3.6 million shares, opposes more leadership changes
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Southwest director buys 3.6 million shares, opposes more leadership changes
Oct 2, 2024 9:32 PM

NEW YORK (Reuters) - Southwest Airlines Director Rakesh Gangwal, who was picked by the company to join its board amid growing pressure from an activist investor, bought more than $100 million in stock and said on Wednesday more top level leadership changes would be "counterproductive."

Gangwal, who co-founded low-cost Indian carrier InterGlobe Aviation, or IndiGo, purchased 3.6 million Southwest ( LUV ) shares on September 30 and October 1 according to Securities and Exchange Commission filings. He paid between $29 and $30 a share.

He said he made the purchases as soon as the so-called trading window when directors and other insiders are permitted to buy and sell the stock opened.

Southwest ( LUV ) put Gangwal on the board in July as activist investor Elliott Investment Management increased pressure on the carrier, demanding leadership and strategy changes to improve financial performance. The company last month announced a board overhaul and other changes.

Last month Southwest ( LUV ) said executive chairman Gary Kelly will step down and six other directors will retire from its 15-member board.

Elliott has held firm to demands for more changes in the top ranks, including the ouster of CEO Bob Jordan. Last week it said it plans to request a special shareholder meeting to press for those changes.

Gangwal told Reuters on Wednesday that more upheaval in the executive suite and boardroom would hurt shareholders. "I believe changing the board structure and top leadership beyond what has been already announced, would be counterproductive and not in the best interest of shareholders."

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
CrowdStrike, Roblox, GE Vernova, Nebius Among 30 Firms That Will Define AI Future, Wedbush Says
CrowdStrike, Roblox, GE Vernova, Nebius Among 30 Firms That Will Define AI Future, Wedbush Says
Aug 18, 2025
07:00 AM EDT, 08/18/2025 (MT Newswires) -- CrowdStrike ( CRWD ) , Roblox ( RBLX ) , GE Vernova ( GEV ) , and Nebius ( NBIS ) are among 30 companies that will define the future of the artificial intelligence theme over the coming years, Wedbush analysts wrote in a note Sunday. Webush said that CrowdStrike ( CRWD )...
Trimble Names Kenny Bement as Chief Accounting Officer
Trimble Names Kenny Bement as Chief Accounting Officer
Aug 18, 2025
07:03 AM EDT, 08/18/2025 (MT Newswires) -- Trimble (TRMB) said Monday it named Kenny Bement as its chief accounting officer, effective next month. Bement succeeds Julie Shepard, who will retire from the company in early 2026 after more than 18 years, the company said. Bement and Shepard will work together over the next six to eight months to ensure a...
Eletrobras partners with C3 AI to modernize Brazil's power grid
Eletrobras partners with C3 AI to modernize Brazil's power grid
Aug 18, 2025
SAO PAULO, Aug 18 (Reuters) - Brazilian power company Eletrobras has partnered with C3 AI to apply artificial intelligence to help operate the electric power transmission network in Latin America's largest economy, the two companies told Reuters on Monday. Eletrobras, Brazil's largest operator in the segment, will implement the C3 AI Grid Intelligence tool, which focuses on monitoring and resolving...
Natera Says Bladder Cancer Phase III Study Shows Positive Results
Natera Says Bladder Cancer Phase III Study Shows Positive Results
Aug 18, 2025
07:01 AM EDT, 08/18/2025 (MT Newswires) -- Natera ( NTRA ) said Monday that topline results from a phase III clinical trial in muscle-invasive bladder cancer showed a statistically significant and clinically meaningful improvement in disease-free and overall survivals for Signatera-positive patients treated with atezolizumab. The trial uses the Signatera ctDNA test in patients with muscle-invasive bladder cancer to detect...
Copyright 2023-2026 - www.financetom.com All Rights Reserved